Mindstate Design Labs is pioneering a new approach to psychedelics by leveraging machine learning and human expertise to create repeatable mental states from these substances. The company analyzes trip reports and pharmacological data to predict how different psychedelic compounds affect consciousness. With FDA approval for a Phase 1 clinical trial focusing on 'moxy' (5-MeO-MiPT), the company hopes to design novel psychedelics tailored for specific therapeutic outcomes, exploring the underlying mechanisms of consciousness itself through its innovative platform, Osmanthus.
Mindstate’s goal is to transform unpredictable psychedelic experiences into precise, repeatable states of mind that can improve mental health treatments.
The heart of Mindstate's innovation is Osmanthus, a large language model designed to predict psychedelic experiences by analyzing thousands of trip reports.
Collection
[
|
...
]